Results 191 to 200 of about 72,405 (280)
Neighborhood Socioeconomic Status and Short‐Term Functional Outcomes in Systemic Lupus Erythematosus
Objective Individuals with systemic lupus erythematosus (SLE) can accumulate functional status (FS) impairment. We evaluated the association between neighborhood socioeconomic disadvantage, as measured by the Area Deprivation Index (ADI), and FS in a national SLE sample.
Baljeet Rai +7 more
wiley +1 more source
Beyond first-line biologic therapy: does treatment sequence matter in ulcerative colitis? [PDF]
Park YE.
europepmc +1 more source
Objective This study aimed to describe real‐world trends in preconception and prenatal use of antirheumatic drugs among pregnant individuals with rheumatic diseases in Ontario, Canada. Methods We conducted a time‐series analysis using repeated cross‐sectional data to examine annual patterns of disease‐modifying antirheumatic drug (DMARD) use among ...
Shenthuraan Tharmarajah +6 more
wiley +1 more source
Early infliximab levels and clearance predict outcomes in acute severe ulcerative colitis. [PDF]
Al Hayek M, Elhadi M.
europepmc +1 more source
Objective To characterize the clinical features, treatment, and outcomes of a large, international cohort of childhood‐onset Takayasu arteritis (cTAK). Methods Patients with a diagnosis of cTAK were identified in A Registry of Childhood Vasculitis and divided into subcohorts by era‐of diagnosis: pre‐biologic (PB; 1986–2006), early biologic (EB; 2007 ...
James Bistolarides +29 more
wiley +1 more source
Simultaneous Quantification of Vedolizumab, Ustekinumab, and Infliximab in Human Serum by LC-MS/MS: Application to Therapeutic Drug Monitoring in Inflammatory Bowel Disease. [PDF]
Zhang Y +7 more
europepmc +1 more source
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher +12 more
wiley +1 more source
The TITAN Study: Topical Infliximab for the Treatment of Advanced Corneal Melt and Ocular Surface Inflammation. [PDF]
Bouhout S +4 more
europepmc +1 more source

